RAPT Therapeutics (RAPT) – Hot Comments
-
Stifel Starts Rapt Therapeutics (RAPT) at Buy, 'RPT193 Has a Shot at Being a First-in-Class Non-JAK Oral for Atopic Dermatitis'
-
JPMorgan Starts Rapt Therapeutics (RAPT) at Overweight
-
-
-
Back to RAPT Stock Lookup